Estrogen and Skin: How HRT Changes Collagen

A 51-year-old patient sat down across from me last spring and said her face had "fallen" in the last eighteen months. That was her word — fallen. She had been doing the same skincare routine for a decade, eating the same way, sleeping roughly the same. The change in her skin had not come gradually. It had come in a window. She had been told by an aesthetician that she needed filler. By a friend that she needed Botox. By her primary care provider that she was "just getting older." None of those were entirely wrong, but none of them addressed what had actually changed: her ovarian estradiol production had collapsed, and the structural protein scaffold of her skin had lost its primary endocrine signal.

I want to walk through what estrogen actually does in skin, what happens when it disappears, what hormone optimization can and cannot do for skin quality, and how I think about this question when a patient brings it into my office.

What estrogen actually does in skin tissue

Skin is an estrogen-responsive organ. Estrogen receptors — both alpha and beta subtypes — are present throughout the epidermis, dermis, and on dermal fibroblasts, the cells responsible for producing collagen, elastin, and the ground substance that gives skin its volume and resilience. When estradiol binds those receptors, it drives a specific set of downstream effects:

• Increased collagen synthesis, particularly type I and type III collagen
• Increased dermal hyaluronic acid production, which holds water in the dermis
• Improved fibroblast activity and turnover
• Increased sebum production and improved barrier function
• Enhanced wound healing and reduced inflammatory signaling
• Maintained dermal vasculature and microcirculation

When estradiol levels drop — which they do, sharply and predictably, in the perimenopausal and postmenopausal transition — every one of those processes downshifts. The result is the cluster of changes patients describe in plain language: thinner skin, drier skin, less spring-back, finer lines that suddenly arrive in groups, increased fragility, slower healing, and an overall loss of the soft tissue volume that defined the face for the previous several decades.

The numbers — how much collagen, how fast

This is the part of the conversation that surprises most patients. Published research is consistent on the magnitude of the change. Skin collagen content drops approximately 30% in the first five years after menopause. Annual skin collagen loss after that initial drop continues at roughly 2% per year, layered on top of the photoaging that has been accumulating throughout life. Dermal thickness decreases proportionally. Skin water content drops as hyaluronic acid synthesis slows.

That 30% figure is the one I want patients to sit with. The skin you have at age 50 is not the skin you had at 45 with five extra years of wear. It is structurally different tissue. The collagen scaffolding that held your face in place has, in many patients, lost almost a third of its mass in a relatively narrow window. Skincare and topical interventions cannot replace that. They can support what is left and slow what is leaving, but the upstream signal is the missing piece.

This is also why the patients I see who started hormone optimization early in the perimenopausal transition tend to have skin that aged differently than patients who started ten years later. Restoring the signal before the structural protein loss has fully played out preserves more of the underlying tissue. Restoring the signal after a decade of postmenopausal collagen loss can still help — but the gains are more modest, and the patient and I both need to be honest about that.

What HRT actually does for skin — and what it does not

When I evaluate a patient asking about hormones for skin, I want to be specific about what the evidence supports. Properly dosed estrogen replacement, in patients who are appropriate candidates, has been shown to:

• Increase dermal collagen content
• Increase skin thickness on biopsy
• Improve skin elasticity on objective measurement
• Improve skin hydration and barrier function
• Reduce the appearance of fine lines, particularly in the periorbital and perioral regions

What HRT does not do:

• Reverse photoaging that has already accumulated
• Replace the volume loss of bone resorption and fat pad atrophy in the mid-face
• Address pigmentation issues like melasma (in fact, exogenous estrogen can sometimes worsen melasma, which is why I screen for it before initiating)
• Substitute for the procedural and topical work that addresses surface-level concerns
• Produce the dramatic transformation patients sometimes hope for

The honest framing: HRT for skin is structural. It rebuilds and preserves the underlying scaffolding. It is not a cosmetic intervention. The patients who do best combine hormone optimization with consistent sun protection, evidence-based topical work (retinoids, vitamin C, peptides), and selectively chosen procedural interventions. The hormone piece makes the rest of it work better because the tissue is healthier underneath.

The mechanism — why oral, transdermal, and pellet routes give different results

This matters more than most patients are told. The route of delivery for estrogen replacement changes the pharmacology in ways that affect skin response.

Oral estrogen undergoes first-pass metabolism through the liver. This produces metabolites and increases hepatic protein synthesis (including SHBG, which can lower free testosterone availability). It also raises certain clotting factors. For skin specifically, oral delivery is effective but carries a different risk profile than transdermal.

Transdermal estrogen (patches, creams, gels) bypasses first-pass metabolism, produces more physiologic estradiol levels, and avoids most of the SHBG elevation. For most patients I evaluate for hormone optimization with skin as a primary concern, transdermal is the starting point.

Pellet therapy — including Biote pellet therapy — delivers steady-state hormone over months and is appropriate for selected patients. The decision between transdermal and pellet is about lifestyle, dosing precision, and patient preference, not a fundamental clinical superiority of one over the other. Both can be done well. Both can be done poorly.

The clinical decision is individualized. The default protocol that one provider uses for everyone is almost never the right protocol for any specific patient.

What I look for at the first visit

When a patient comes in primarily concerned about skin and hormonal aging, the workup I order is the same comprehensive panel I order for any mid-life hormone consultation. I am not just checking estradiol — I am building a picture. The panel includes:

• Estradiol, progesterone, total and free testosterone, SHBG, DHEA-S
• FSH and LH (which tell me where you actually are in the menopausal transition)
• Full thyroid: TSH, free T3, free T4, reverse T3, thyroid antibodies
• Fasting insulin, HbA1c, lipid panel
• Vitamin D, ferritin, B12
• hs-CRP

I am also asking about menstrual history (when did cycles change, when did they stop, was there any bleeding pattern that was unusual), surgical history (particularly hysterectomy or oophorectomy, which changes the framework substantially), family history, prior hormone exposure, current medications and supplements, sleep quality, and any vasomotor symptoms.

For skin specifically, I want to know how the change presented. A patient whose skin shifted suddenly within six months of cycle changes is a different conversation than a patient whose skin has been gradually thinning over a decade. The pattern points to where in the transition we are intervening.

Who is a good candidate — and who is not

I am direct with patients about candidacy because the alternative is treating people who should not be treated. Good candidates for HRT with skin among the goals include:

• Perimenopausal or postmenopausal patients with documented hormonal decline on labs
• Symptom burden beyond skin alone — sleep, energy, cognitive, vasomotor, libido — that adds up to a clinical picture
• Realistic expectations about what hormones can and cannot do for skin
• Absence of contraindications: estrogen-receptor-positive cancer history, active or recent thromboembolic disease, certain liver conditions, undiagnosed abnormal uterine bleeding
• Willingness to do follow-up labs at three months and engage with the long-term clinical relationship

Patients who are not appropriate candidates for HRT may still be candidates for men's testosterone replacement considerations if they are male partners who are noticing similar changes, or for non-hormonal interventions including procedural work, topical optimization, and adjacent metabolic support.

How treatment proceeds in practice

I start conservatively. A patient initiating transdermal estradiol typically begins at the lower end of the standard dose range, with progesterone alongside if the patient has an intact uterus or if the clinical picture indicates it for sleep and tissue effects. We recheck labs at three months — not just hormone levels but the full metabolic picture — and adjust from there.

For skin specifically, the timeline is longer than the symptom timeline. Sleep improves in weeks. Energy and mood typically improve by six to eight weeks. Skin changes — thickness, hydration, elasticity — take three to six months to become visible to the patient and longer to peak. Patients who expect a four-week skin transformation will be disappointed by what is actually a slow rebuilding process. Patients who understand the timeline see real change at six months and continued improvement at twelve.

The clinical next step

If you are noticing a change in your skin that arrived alongside other mid-life shifts — sleep disruption, central weight gain, fatigue, mood changes, vasomotor symptoms — the workup that addresses skin is the same workup that addresses the rest of the picture. A skin-only conversation almost always misses the point.

Book a consultation and bring any prior labs, your menstrual and surgical history, and a list of every medication and supplement you are taking. We will run the comprehensive lab work if you do not have recent results, and the second visit will be a real conversation about what the numbers show and what the right plan is.

TW

Travis Woodley

MSN, RN, CRNP — Platinum Biote Provider — Founder, Revitalize

Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.

Book a ConsultationCall (762) 261-3880

About Travis →More articles →Rebuild Institute →